+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orphan Drugs Market - Global Forecast 2026-2032- Product Image
Orphan Drugs Market - Global Forecast 2026-2032- Product Image
New

Orphan Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674387
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The orphan drugs market is transforming, driven by scientific advances, regulatory evolution, and a heightened emphasis on patient-centered, value-focused pharmaceutical solutions. For senior leaders, adapting to new complexities and aligning decision-making across the product lifecycle are pivotal to navigating this environment and achieving sustainable advantage.

Market Snapshot: Orphan Drugs Market Trends and Growth

The orphan drugs market demonstrates robust expansion, with value forecasted to rise from USD 181.56 billion in 2025 to USD 193.04 billion in 2026. Continued momentum, marked by a CAGR of 6.80%, is expected to drive the market to USD 287.78 billion by 2032. This trajectory underscores the impact of scientific innovation, progressive regulatory frameworks, and increasing prioritization of patient outcomes. Orphan drugs now represent a critical focus for senior market stakeholders who seek high-growth opportunities and resilient investment in life sciences.

Scope & Segmentation of the Orphan Drugs Market

This report delivers a strategic breakdown of the orphan drugs market, examining scientific, regulatory, and commercial dynamics to inform executive planning. Key segments include:

  • Therapeutic Areas: Immunology, Infectious Diseases, Metabolic Disorders, Neurology, Oncology. Each area exhibits distinctive market access challenges and development considerations, impacting everything from regulatory compliance to commercialization potential.
  • Product Types: Biologics (detailed analysis covers Enzymes, Monoclonal Antibodies, and Recombinant Proteins), Gene Therapy (Non-Viral, Viral Vectors), Small-Molecule, and Tissue Therapy. These types differ in technological complexity and regulatory hurdles, often necessitating customized investment and operational planning.
  • Administration Routes: Inhalation, Injectable (comprising intramuscular, intravenous, subcutaneous), Oral, and Topical. The chosen route influences patient adherence, specialty distribution, and mode-of-care requirements.
  • Distribution Channels: Direct-To-Patient, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Channels define supply chain dynamics and influence both inventory management and patient adherence systems.
  • Patient Demographics: Adult, Pediatric. Segments require differentiated dosage regimes, clinical trial approaches, and caregiver involvement strategies to optimize outcomes and compliance.
  • Payer Types: Government Programs, Out-of-Pocket, Private Insurance. Each payer model affects reimbursement, contracting, and risk-sharing arrangements, driving the need for tailored access and value demonstration strategies.
  • Regional Coverage: Americas, EMEA, Asia-Pacific. Variations in regulation, local policy, and manufacturing capabilities require region-specific approaches to product registration, pricing, and operational readiness.

Key Takeaways for Executive Decision-Makers

  • Effective cross-functional collaboration, bridging medical, regulatory, and supply chain functions, is essential to convert innovations into therapies that reach underserved patient groups.
  • Advanced technologies—including emerging gene therapies and complex biologics—are raising the bar for manufacturing rigor and process efficiency, prompting further capital investment in scalable operations.
  • Expedited approval pathways offer early patient access, but necessitate ongoing evidence generation through real-world data and post-marketing surveillance to support long-term value claims.
  • Payer expectations are evolving toward outcomes-based agreements, requiring organizations to integrate advanced data capture and analytics within their commercial models to demonstrate therapeutic benefit.
  • Expanding patient support frameworks and digital monitoring, often via specialty pharmacy collaboration, ensures higher adherence and enables richer insights into therapy effectiveness and value.
  • Segmentation allows organizations to develop more agile commercial strategies, tailoring clinical development, distribution, and contracting to diverse populations and geographies.

Tariff Impact: U.S. Policy Developments and Supply Chain Adaptation

Recent U.S. tariff policy changes affecting orphan drug inputs have reshaped global procurement strategies. Manufacturers dependent on international sources for active ingredients, key intermediates, or equipment are revising their supply networks, adopting dual-sourcing or enhancing regional production. These adaptations drive closer collaboration between legal, regulatory, and procurement teams to strengthen contracts, validate new manufacturing sites, and ensure compliance. Such measures reinforce the resilience of supply chains and support the uninterrupted provision of critical therapies.

Methodology & Data Sources

This analysis draws on a mixed-methods approach, combining stakeholder interviews with industry leaders and clinicians, alongside systematic review of clinical literature and regulation. Scenario assessment and expert validation frame all outputs to provide practical, actionable perspectives for executive decision-making.

Why This Report Matters

  • Empowers C-level leaders to proactively identify operational challenges and align strategic investment with shifting market and regulatory environments.
  • Supports the creation of robust commercialization and value demonstration strategies adaptable to evolving segmentation and regional requirements.
  • Helps organizations build resilience and clarity amid accelerating clinical, policy, and payer landscape change.

Conclusion

Integrating robust evidence generation, resilient supply chains, and patient-centered capabilities is fundamental for long-term leadership in orphan drugs. Cross-functional planning equips organizations to realize value and maintain a strong competitive stance within this complex sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Orphan Drugs Market, by Therapeutic Area
8.1. Immunology
8.2. Infectious Diseases
8.3. Metabolic Disorders
8.4. Neurology
8.5. Oncology
9. Orphan Drugs Market, by Product Type
9.1. Biologics
9.1.1. Enzymes
9.1.2. Monoclonal Antibodies
9.1.3. Recombinant Proteins
9.2. Gene Therapy
9.2.1. Non-Viral Vector
9.2.2. Viral Vector
9.3. Small-Molecule
9.4. Tissue Therapy
10. Orphan Drugs Market, by Administration Route
10.1. Inhalation
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
10.3. Oral
10.4. Topical
11. Orphan Drugs Market, by Patient Type
11.1. Adult
11.2. Pediatric
12. Orphan Drugs Market, by Payer Type
12.1. Government Programs
12.2. Out-Of-Pocket
12.3. Private Insurance
13. Orphan Drugs Market, by Distribution Channel
13.1. Direct-To-Patient
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Orphan Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Orphan Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Orphan Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Orphan Drugs Market
18. China Orphan Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. AstraZeneca PLC
19.8. Bayer AG
19.9. BioMarin Pharmaceutical Inc.
19.10. Bristol-Myers Squibb Company
19.11. Eli Lilly and Company
19.12. F. Hoffmann-La Roche Ltd.
19.13. GlaxoSmithKline plc
19.14. Novartis AG
19.15. Novo Nordisk A/S
19.16. Pfizer Inc.
19.17. Sanofi S.A.
19.18. Takeda Pharmaceutical Company Limited
19.19. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS ORPHAN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 151. EUROPE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 171. AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 185. ASEAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 186. ASEAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 187. ASEAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 188. ASEAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 189. ASEAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 190. ASEAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 192. ASEAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. GCC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. GCC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 195. GCC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 196. GCC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 197. GCC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 198. GCC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 199. GCC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 200. GCC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 201. GCC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. BRICS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. BRICS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 215. BRICS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. BRICS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 217. BRICS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 218. BRICS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 219. BRICS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 220. BRICS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 221. BRICS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 222. BRICS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. G7 ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. G7 ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 225. G7 ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 226. G7 ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 227. G7 ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 228. G7 ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 229. G7 ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 230. G7 ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 231. G7 ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 232. G7 ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. NATO ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. NATO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 235. NATO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 236. NATO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 237. NATO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 238. NATO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 239. NATO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 240. NATO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 241. NATO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 242. NATO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. CHINA ORPHAN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. CHINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 256. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 257. CHINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 258. CHINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 259. CHINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 260. CHINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 261. CHINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 262. CHINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2032 (USD MILLION)
TABLE 263. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Orphan Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 193.04 Billion
Forecasted Market Value ( USD ) by 2032 $ 287.78 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Orphan Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Orphan Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Orphan Drugs Service Market Report 2025 - Product Image

Orphan Drugs Service Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Orphan Drugs - Global Strategic Business Report - Product Image

Orphan Drugs - Global Strategic Business Report

  • Report
  • 409 Pages
  • Global
From
Orphan Drugs Market Report 2025 - Product Image

Orphan Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033 - Product Image

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From

About the Orphan Drug Market

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.